Celsion appoints Dr. Corinne Le Goff as President and CEO; Tardugno becomes Executive Chairman

Imunon, Inc.

Dr. Le Goff, former CCO of Moderna, named CEO effective July 18, 2022.
New CEO base salary $624,000, signing bonus $50,000, target bonus 72% of base.
Inducement grants: option to buy 177,000 shares at $1.95; 53,000 restricted shares.
Michael Tardugno transitions to Executive Chairman with base salary of $500,000 (prorated to $240,000 in 2022).
Relocation allowance up to $75,000 for two years; severance of one year's salary upon termination without cause.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Michael H. Tardugno

Executive Chairman

IMNN · Imunon, Inc.

Effective: 2022-07-18
Filed: July 19, 2022, 7:59 PM ET

Michael H. Tardugno, the Company’s current Chairman, President and Chief Executive Officer, will transition from his current role to the position of Executive Chairman of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael H. Tardugno changed role as Executive Chairman at Imunon, Inc..

Action: transitioned
Role: Executive Chairman

Exact text from the filing

Michael H. Tardugno, the Company’s current Chairman, President and Chief Executive Officer, will transition from his current role to the position of Executive Chairman of the Board.

View on SEC.gov

Imunon, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-019765

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.